Home > Newsletters > Washington Drug Letter > FDA Finalizes Guidance Supporting Superiority Trials for ABS Drugs
Washington Drug Letter
Oct. 15, 2012 | Vol. 44 No. 41
FDA Finalizes Guidance Supporting Superiority Trials for ABS Drugs
Sponsors of clinical studies for antimicrobial drugs to treat acute bacterial sinusitis (ABS) should use superiority trials and demonstrate that the candidate affects the clinical course of the disease, according to finalized FDA guidance on the topic.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.